Cervical cancer rates are on the rise among younger women, owing in part to a lack of screening and prevention.

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

Current guidelines lack consensus and rely on lower-quality evidence, according to the author of new research.

Recurrent or metastatic cervical cancer is a devastating disease, and patients can face a difficult treatment journey with limited options,” said Ignace Vergote, M.D., Ph.D., University Hospitals ...

The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...

“The commonest cancer we have that affects women and even kills them is cancer of the cervix. On average, we see four to five ...

Poland’s cervical cancer prevention programme has been upgraded, offering improved early detection and education to reinforce ...

Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...